Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6769 Mesa Ridge Rd. SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.inovio.com |
IR: | See website |
Key People | ||
Jacqueline Elizabeth Shea President, Chief Executive Officer, Director | Peter D. Kies Chief Financial Officer | Laurent M. Humeau Chief Scientific Officer | Michael Sumner Chief Medical Officer |
Business Overview |
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models. |
Financial Overview |
For the fiscal year ended 31 December 2023, Inovio Pharmaceuticals Inc revenues decreased 92% to $832K. Net loss decreased 52% to $135.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Other Research and development decrease of 54% to $82.2M (expense), General and administrative - Balancing v decrease of 46% to $41.7M (expense), G/L on Invest HFS. |
Employees: | 122 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $116.66M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.83M as of Dec 31, 2023 |
EBITDA (TTM): | -$128.66M as of Dec 31, 2023 |
Net annual income (TTM): | -$135.12M as of Dec 31, 2023 |
Free cash flow (TTM): | -$124.69M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 25,329,333 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |